Market closed
Century Therapeutics/$IPSC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Ticker
$IPSC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
145
Website
IPSC Metrics
BasicAdvanced
$43M
-
-$1.61
1.75
-
Price and volume
Market cap
$43M
Beta
1.75
52-week high
$3.70
52-week low
$0.34
Average daily volume
500K
Financial strength
Current ratio
1.495
Quick ratio
1.47
Long term debt to equity
30.342
Total debt to equity
33.36
Management effectiveness
Return on assets (TTM)
-23.67%
Return on equity (TTM)
-73.14%
Valuation
Price to revenue (TTM)
5.98
Price to book
0.27
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-0.357
Growth
Revenue change (TTM)
194.81%
Earnings per share change (TTM)
-30.16%
3-year earnings per share growth (CAGR)
-18.37%
What the Analysts think about IPSC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Century Therapeutics stock.
IPSC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IPSC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IPSC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Century Therapeutics stock?
Century Therapeutics (IPSC) has a market cap of $43M as of April 17, 2025.
What is the P/E ratio for Century Therapeutics stock?
The price to earnings (P/E) ratio for Century Therapeutics (IPSC) stock is 0 as of April 17, 2025.
Does Century Therapeutics stock pay dividends?
No, Century Therapeutics (IPSC) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Century Therapeutics dividend payment date?
Century Therapeutics (IPSC) stock does not pay dividends to its shareholders.
What is the beta indicator for Century Therapeutics?
Century Therapeutics (IPSC) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.